Broderick Brian C cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,889 shares of the company’s stock after selling 300 shares during the period. Broderick Brian C’s holdings in Eli Lilly and were worth $732,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Beutel Goodman & Co Ltd. bought a new stake in shares of Eli Lilly and during the first quarter valued at about $161,084,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC increased its stake in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares in the last quarter. 75.61% of the stock is owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.47% during mid-day trading on Friday, reaching $81.15. 2,446,392 shares of the company’s stock were exchanged. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The company has a market cap of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34. The company’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.72.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the business posted $0.86 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. Eli Lilly and’s payout ratio is 90.04%.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Position Cut by Broderick Brian C” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.watchlistnews.com/eli-lilly-and-company-lly-position-cut-by-broderick-brian-c/1479540.html.

Several equities research analysts have recently issued reports on the stock. Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reissued an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a research report on Sunday, May 21st. Cowen and Company increased their price objective on shares of Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a research report on Monday, April 17th. TheStreet downgraded shares of Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. Finally, BMO Capital Markets reissued an “underperform” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. In the last quarter, insiders sold 669,733 shares of company stock valued at $55,845,287. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.